Abstract
Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Serelaxin: New Investigational Treatment in Acute Heart Failure
Volume: 11 Issue: 3
Author(s): Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Abstract: Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Export Options
About this article
Cite this article as:
Said Sarmad and Mukherjee Debabrata, Serelaxin: New Investigational Treatment in Acute Heart Failure, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/1871525711666131128144132
DOI https://dx.doi.org/10.2174/1871525711666131128144132 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recreational Use, Analysis and Toxicity of Tryptamines
Current Neuropharmacology Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Current Cardiology Reviews Statins in Aortic Stenosis
Current Pharmaceutical Design Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators
Current Drug Targets Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Analysis of the L-Arginine / Nitric Oxide Pathway: The Unique Role of Mass Spectrometry
Current Pharmaceutical Analysis Vascular microRNAs
Current Drug Targets Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Powerful Technique to Test Selectivity of Agents Acting on Cardiac Ion Channels: The Action Potential Voltage-Clamp
Current Medicinal Chemistry The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design The Role of iNOS in Chronic Inflammatory Processes In Vivo: Is it Damage-Promoting, Protective, or Active at all?
Current Molecular Medicine Role of Heart Rate Reduction in the Management of Myocarditis
Current Pharmaceutical Design Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascular Endothelium: Functioning in Norm, Changes in Atherosclerosis and Current Dietary Approaches to Improve Endothelial Function
Mini-Reviews in Medicinal Chemistry